INTRODUCTION: @entity2976 ( @entity2976 ) is a rare complication of long-term peritoneal dialysis usually associated with the inadequacy and early termination of dialysis modality. Adequate treatment of peritoneal @entity82 has not been achieved by medical intervention so far. @entity618 ( @entity2098 ), which inhibits @entity15129 dehydrogenase reversibly and highly selectively, is the most widely used drug for maintenance immunosupression in renal transplantation. Recent studies have shown that @entity2098 has also antifibrotic effects. In this study, we evaluated the effects of @entity2098 on @entity2976 model in @entity35 based on antifibrotic effects. MATERIALS AND METHODS: Twenty-four @entity35 albino @entity35 have been randomly divided into four groups. Group I (control group) received isotonic saline intraperitoneally (i.p) 2  ml/day for (0-3rd weeks). Group II ( @entity1216 (CG) group) received CG 2  ml/day i.p. for (0-3rd weeks). Group III ( @entity1216  +  @entity2098 group) received CG (2  ml/day) i.p. for (0-3rd weeks) plus @entity2098 30  mg/kg/day peroral (4th-6th weeks). Group IV (resting group) received CG 2  ml/day) i.p. (0-3rd weeks) plus peritoneal resting without any treatment (4th-6th weeks) At the end of the sixth weeks, all of the @entity35 were killed. All of the groups were analyzed in terms of peritoneal thickness, degree of @entity32 , @entity455 , @entity2295 and @entity82 . Also, the parietal peritoneal tissue samples were evaluated for @entity11017 ( @entity11017 ) by using the immunohistochemical analysis. RESULTS: When the CG group was compared with the @entity2098 group, the medication resulted in a statistically significant reduction in peritoneal thickness, @entity32 and @entity82 score (53.23      16.24 vs. 17.22      3.62, 1      1.225 vs. 1      0, 1.6      0.548 vs. 0.2      0.447, respectively, all p  <  0.05). In the resting group, no beneficial effects on morphological abnormality of the peritoneum were observed as compared with @entity2098 group. However, according to immunohistochemical analysis of the expression of @entity11017 on peritoneal samples, the highest expression of @entity11017 was observed in the @entity2098 group. CONCLUSION: @entity2098 was effective for the treatment of encapsulating peritoneal @entity82 in our @entity35 model. Most recently, @entity2098 may be first choice for @entity2976 due to antifibrotic effect.

The use of XXXX in experimental encapsulating peritoneal sclerosis.

@entity1216 :: ('MESH:D002710', 'Chemical') :: ['chlorhexidine'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vasculopathy'] @entity35 :: ('10116', 'Species') :: ['rat', 'Wistar', 'rats'] @entity2976 :: ('MESH:D056627', 'Disease') :: ['EPS', 'Encapsulated peritoneal sclerosis'] @entity2295 :: ('MESH:D015861', 'Disease') :: ['neovascularization'] @entity2098 :: ('CHEBI:8764', 'Chemical') :: ['MMF'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['Mycophenolate mofetil'] @entity15129 :: ('MESH:D007291', 'Chemical') :: ['inosine monophosphate'] @entity11017 :: ('81686(Tax:10116)', 'Gene') :: ['MMP-2', 'matrix metalloproteinase 2']
@entity618 :: (MESH:C063008,Chemical) :: ['mycophenolate mofetil']
